• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

子宫内膜样型子宫内膜癌患者的长期生存情况。

Long-term survival of endometrioid endometrial cancer patients.

机构信息

Palliative Care Unit, Chair of Oncology, Medical University of Lodz, Poland.

出版信息

Arch Med Sci. 2010 Dec;6(6):937-44. doi: 10.5114/aoms.2010.19305. Epub 2010 Dec 29.

DOI:10.5114/aoms.2010.19305
PMID:22427770
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3302708/
Abstract

INTRODUCTION

To establish risk factors for onset and progression of endometrioid endometrial cancer still remains the aim of scientists. The aim of the study was to determine disease-free survival (DFS) and overall survival (OS) in women with endometrioid endometrial cancer.

MATERIAL AND METHODS

A retrospective review of 142 patients with endometrioid endometrial cancer after surgery treated with adjuvant radiotherapy and/or chemotherapy in the Regional Cancer Centre in Lodz between 2002 and 2004 was performed. Clinical and pathological data were correlated with clinical outcome and survival.

RESULTS

In 3 patients (2.1%) clinical progression was diagnosed during the treatment. In 23 patients (16.7%) after primary remission, relapse was diagnosed 2-56 months after treatment. DFS and OS were 81.7% and 83.1% respectively. Better DFS significantly correlated with larger number of pregnancies (> 1), stage I of the disease and optimal surgery. Lower stage of disease, pelvic lymph node dissection, optimal surgery and depth of myometrial infiltration ≤ 50% were independent prognostic factors for better OS.

CONCLUSIONS

The results of our study provided significant evidence that early detection of endometrioid endometrial cancer enables optimal surgery. It reduces the indications for adjuvant therapy in stage I of the disease, and makes the prognosis significantly better. Other clinical and pathological factors such as numerous pregnancies, pelvic lymphadenectomy, and depth of myometrial infiltration, although important, are of less significance. Further prospective, randomized studies are necessary to prove the role of these factors.

摘要

简介

确定子宫内膜样型子宫内膜癌发病和进展的风险因素仍然是科学家们的目标。本研究旨在确定接受辅助放疗和/或化疗的子宫内膜样型子宫内膜癌女性的无病生存(DFS)和总生存(OS)。

材料与方法

对 2002 年至 2004 年期间在罗兹地区癌症中心接受手术治疗后接受辅助放疗和/或化疗的 142 例子宫内膜样型子宫内膜癌患者进行回顾性分析。将临床和病理数据与临床结果和生存相关联。

结果

在 3 名患者(2.1%)中,在治疗过程中诊断出临床进展。在 23 名患者(16.7%)在初次缓解后,在治疗后 2-56 个月诊断出复发。DFS 和 OS 分别为 81.7%和 83.1%。DFS 更好与更多的妊娠次数(>1)、疾病 I 期和最佳手术显著相关。更好的 OS 与较低的疾病分期、盆腔淋巴结清扫术、最佳手术和肌层浸润深度≤50%独立相关。

结论

我们的研究结果提供了重要证据,表明早期发现子宫内膜样型子宫内膜癌可实现最佳手术。这减少了疾病 I 期辅助治疗的指征,并显著改善了预后。其他临床和病理因素,如多次妊娠、盆腔淋巴结切除术和肌层浸润深度,虽然重要,但意义较小。有必要进行进一步的前瞻性、随机研究以证明这些因素的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c0/3302708/d90bbb8029c5/AMS-6-6-937_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c0/3302708/e9038236850a/AMS-6-6-937_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c0/3302708/ed0b47ea8ecc/AMS-6-6-937_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c0/3302708/ab3c10fccbd8/AMS-6-6-937_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c0/3302708/d90bbb8029c5/AMS-6-6-937_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c0/3302708/e9038236850a/AMS-6-6-937_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c0/3302708/ed0b47ea8ecc/AMS-6-6-937_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c0/3302708/ab3c10fccbd8/AMS-6-6-937_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9c0/3302708/d90bbb8029c5/AMS-6-6-937_F4.jpg

相似文献

1
Long-term survival of endometrioid endometrial cancer patients.子宫内膜样型子宫内膜癌患者的长期生存情况。
Arch Med Sci. 2010 Dec;6(6):937-44. doi: 10.5114/aoms.2010.19305. Epub 2010 Dec 29.
2
[Survival, prognostic factors and modern tendencies in adjuvant treatment of diagnosed endometrial cancer patients with or without lymph node dissection].[确诊子宫内膜癌患者行或未行淋巴结清扫术辅助治疗的生存情况、预后因素及现代趋势]
Akush Ginekol (Sofiia). 2009;48 Suppl 1:3-11.
3
[Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].同步原发性子宫内膜癌和卵巢癌的临床病理及生存分析
Zhonghua Fu Chan Ke Za Zhi. 2018 Dec 25;53(12):816-822. doi: 10.3760/cma.j.issn.0529-567x.2018.12.004.
4
Role of adjuvant therapy in stage IIIC2 endometrial cancer.辅助治疗在 IIIC2 期子宫内膜癌中的作用。
Int J Gynecol Cancer. 2020 Aug;30(8):1169-1176. doi: 10.1136/ijgc-2020-001446. Epub 2020 Jul 9.
5
Tumor size: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer.肿瘤大小:在国际妇产科联合会(FIGO)Ⅰ期子宫内膜样腺癌中,比肌层浸润深度更好的远处失败和死亡的独立预测因素。
Int J Gynecol Cancer. 2013 May;23(4):690-7. doi: 10.1097/IGC.0b013e31828c85c6.
6
Lymphadenectomy as a prognostic marker in uterine non-endometrioid carcinoma.淋巴结切除术作为子宫非子宫内膜样癌的预后标志物。
Arch Gynecol Obstet. 2012 Jan;285(1):207-14. doi: 10.1007/s00404-011-1914-x. Epub 2011 May 3.
7
[Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].盆腔淋巴结清扫术作为早期子宫内膜癌(I期)中复发性淋巴转移高风险患者辅助放疗的替代方案
Minerva Ginecol. 2009 Feb;61(1):1-12.
8
Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.辅助阴道近距离放疗治疗 IIB 期分级 2 或 3 期子宫内膜癌的结果和复发模式。
Int J Gynecol Cancer. 2020 Jan;30(1):48-55. doi: 10.1136/ijgc-2019-000675. Epub 2019 Nov 12.
9
Preoperative Leukocytosis as a Prognostic Marker in Endometrioid-Type Endometrial Cancer: A Single-Center Experience from Saudi Arabia.术前白细胞增多作为子宫内膜样型子宫内膜癌的预后标志物:来自沙特阿拉伯的单中心经验
Gulf J Oncolog. 2020 Jan;1(32):51-58.
10
Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.基于盆腔淋巴结清扫彻底程度对子宫内膜样型子宫内膜癌中高危组生存影响的多中心回顾性队列分析。
Gynecol Oncol. 2016 Jun;141(3):440-446. doi: 10.1016/j.ygyno.2016.03.031. Epub 2016 Apr 8.

引用本文的文献

1
Central Nervous System Metastases in Endometrial Carcinoma: A Case Series.子宫内膜癌的中枢神经系统转移:病例系列
Cureus. 2025 Mar 12;17(3):e80464. doi: 10.7759/cureus.80464. eCollection 2025 Mar.
2
Safety and Efficacy of Brachytherapy in Inoperable Endometrial Cancer.近距离放射治疗在无法手术的子宫内膜癌中的安全性和有效性
J Pers Med. 2024 Dec 3;14(12):1138. doi: 10.3390/jpm14121138.
3
A 10-Year Retrospective Cohort Study of Endometrial Cancer Outcomes and Associations with Lymphovascular Invasion: A Single-Center Study from Germany.

本文引用的文献

1
Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group.日本子宫内膜癌术后管理的实践模式:日本妇科肿瘤学组的一项调查
Gynecol Oncol. 2009 Dec;115(3):456-9. doi: 10.1016/j.ygyno.2009.08.016. Epub 2009 Sep 17.
2
Parity and time interval since childbirth influence survival in endometrial cancer patients.分娩次数和产后时间间隔会影响子宫内膜癌患者的生存率。
Int J Gynecol Cancer. 2009 May;19(4):665-9. doi: 10.1111/IGC.0b013e3181a3e1bf.
3
Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer.
一项关于子宫内膜癌结局及与淋巴管侵犯相关性的10年回顾性队列研究:来自德国的单中心研究
Diagnostics (Basel). 2024 Aug 4;14(15):1686. doi: 10.3390/diagnostics14151686.
4
The endometrial cancer detection using non-invasive hypermethylation of and genes in women with postmenopausal bleeding in Northwest China.中国西北地区绝经后出血女性中使用和基因的非侵入性高甲基化检测子宫内膜癌
Cytojournal. 2024 Apr 25;21:15. doi: 10.25259/Cytojournal_78_2023. eCollection 2024.
5
Treatment of endometrial cancer from 2000 to 2020 in Germany: a retrospective population based cohort study.2000 年至 2020 年德国子宫内膜癌的治疗:一项回顾性基于人群的队列研究。
J Cancer Res Clin Oncol. 2024 May 27;150(5):279. doi: 10.1007/s00432-024-05772-9.
6
High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options.高级别子宫内膜癌:分子亚型、当前挑战和治疗选择。
Reprod Sci. 2024 Sep;31(9):2541-2559. doi: 10.1007/s43032-024-01544-5. Epub 2024 Apr 24.
7
Racioethnic Disparities in Endometrial Cancer Outcomes.子宫内膜癌结局中的种族差异。
Diagnostics (Basel). 2024 Feb 14;14(4):417. doi: 10.3390/diagnostics14040417.
8
MicroRNAs, long non-coding RNAs, and circular RNAs and gynecological cancers: focus on metastasis.微小RNA、长链非编码RNA和环状RNA与妇科癌症:聚焦转移
Front Oncol. 2023 Oct 3;13:1215194. doi: 10.3389/fonc.2023.1215194. eCollection 2023.
9
A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and β-catenin nuclear accumulation.一项基于患者来源的类器官的研究通过降低异常 FOXM1 表达和 β-连环蛋白核积累,确定了一种针对 SNORD14E 的反义寡核苷酸(ASO)作为子宫内膜癌的治疗靶点。
J Exp Clin Cancer Res. 2023 Sep 5;42(1):230. doi: 10.1186/s13046-023-02801-2.
10
Development and validation of a prognostic model based on metabolic risk score to predict overall survival of endometrial cancer in Chinese patients.基于代谢风险评分的预测中国子宫内膜癌患者总生存的预后模型的建立和验证。
J Gynecol Oncol. 2023 Nov;34(6):e69. doi: 10.3802/jgo.2023.34.e69. Epub 2023 Jun 5.
III期A组子宫内膜癌复发与生存情况的多中心分析
Gynecol Oncol. 2009 Aug;114(2):279-83. doi: 10.1016/j.ygyno.2009.04.030. Epub 2009 May 15.
4
Postoperative radiotherapy in intermediate and high-risk Stage I endometrial cancer: analysis of prognostic factors and survival.Ⅰ期高危及中危子宫内膜癌术后放疗:预后因素及生存分析
Eur J Gynaecol Oncol. 2008;29(5):505-10.
5
Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis.早期子宫内膜癌术后放疗后的生存及复发性疾病:系统评价与荟萃分析
BJOG. 2007 Nov;114(11):1313-20. doi: 10.1111/j.1471-0528.2007.01332.x. Epub 2007 Sep 5.
6
Survival and prognostic factors of patients treated for Stage I to Stage III endometrial carcinoma in a reference cancer center in Southern Brazil.巴西南部一家参考癌症中心中接受 I 期至 III 期子宫内膜癌治疗患者的生存及预后因素
Eur J Gynaecol Oncol. 2007;28(1):48-50.
7
Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: a multi-institutional analysis of 608 women.早期子宫内膜癌的辅助放疗与生存结局:608例女性的多机构分析
Gynecol Oncol. 2006 Nov;103(2):661-6. doi: 10.1016/j.ygyno.2006.05.002. Epub 2006 Jun 23.
8
Follow-up after primary therapy for endometrial cancer: a systematic review.子宫内膜癌初次治疗后的随访:一项系统评价
Gynecol Oncol. 2006 Jun;101(3):520-9. doi: 10.1016/j.ygyno.2006.02.011. Epub 2006 Mar 23.
9
Systematic review of systemic therapy for advanced or recurrent endometrial cancer.晚期或复发性子宫内膜癌全身治疗的系统评价
Gynecol Oncol. 2006 Apr;101(1):158-67. doi: 10.1016/j.ygyno.2005.11.019. Epub 2006 Jan 24.
10
Screening and the prevention of gynecologic cancer: endometrial cancer.妇科癌症的筛查与预防:子宫内膜癌
Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):363-77. doi: 10.1016/j.bpobgyn.2005.10.015. Epub 2005 Dec 20.